QCG
AVXL icon

Quadrant Capital Group’s Anavex Life Sciences AVXL Stock Holding History

Quadrant Capital Group’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-141
Closed -$433 – 1366
2026
Q1 		$433 Sell
141
-649
-82% -$2.81K ﹤0.01% 2634
2025
Q4 		$2.81K Sell
790
-1,061
-57% -$6.5K ﹤0.01% 2462
2025
Q3 		$16.5K Buy
+1,851
New +$18.8K ﹤0.01% 2007
2025
Q2 		– Sell
-2,611
Closed -$22.4K – 1452
2025
Q1 		$22.4K Buy
2,611
+450
+21% +$4.25K ﹤0.01% 2007
2024
Q4 		$23.2K Buy
2,161
+649
+43% +$4.99K ﹤0.01% 1824
2024
Q3 		$8.59K Hold
1,512
– – ﹤0.01% 2184
2024
Q2 		$6.38K Buy
+1,512
New +$6.12K ﹤0.01% 2237
2024
Q1 		– Sell
-86
Closed -$801 – 2721
2023
Q4 		$801 Buy
+86
New +$592 ﹤0.01% 2573
2018
Q1 		– Sell
-1,705
Closed -$5K – 2160
2017
Q4 		$5K Hold
1,705
– – ﹤0.01% 1446
2017
Q3 		$7K Hold
1,705
– – ﹤0.01% 1318
2017
Q2 		$9K Hold
1,705
– – ﹤0.01% 1132
2017
Q1 		$9K Hold
1,705
– – ﹤0.01% 1102
2016
Q4 		$6K Buy
+1,705
New +$6.07K ﹤0.01% 1175

Other funds holding AVXL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SF
Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Quadrant Capital Group's AVXL Position: Q2 2026 in Review

Quadrant Capital Group sold out of Anavex Life Sciences (AVXL) in Q2 2026, closing a stake of 141 shares — an estimated $433 sold.

Quadrant Capital Group first reported a position in AVXL in Q4 2016 and held it in 13 quarters. The position peaked at $23.2K in Q4 2024. 179 funds tracked by Wall St. Rank hold AVXL as of Q2 2026.

  • Quadrant Capital Group reported no remaining Anavex Life Sciences position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 141 Anavex Life Sciences shares in Q2 2026, an estimated $433.
  • Quadrant Capital Group first reported a position in Anavex Life Sciences in Q4 2016 and held it in 13 quarters.
  • Quadrant Capital Group's Anavex Life Sciences position peaked at $23.2K in Q4 2024.
  • 179 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.